Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. - Wikidata - awgldk - TriplyDB

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.

http://www.wikidata.org/entity/Q37298638

about

Multi-target drugs: the trend of drug research and development Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation.Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.Activity-based kinase profiling of approved tyrosine kinase inhibitors.Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

P2860

Q28480888-D66B4C27-6815-4214-97AF-9BA0CF1920A9 Q28483929-E7C622B6-44D6-4AC1-B4AF-9540DFB01401 Q35171274-D695A3BF-9C9B-43A3-A9C2-AEE252178171 Q36947802-ED6065E8-A6DC-413A-8561-F1DD25755EE2 Q37564600-1F4773BA-8425-4EC4-8618-9194F57FB33E Q42713576-A33901A6-96DC-4099-A8D0-A6E6DD33256E Q48010780-7E6CE878-8666-4110-9996-47D3F72C451B Q51372022-3889C71A-C280-4C3B-8C04-5CBB78EC5E1D Q51373837-F8F20B55-0A3E-4F07-A183-E6FFC9E4C6B6

P2860

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.

http://www.wikidata.org/entity/Q37298638

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Nilotinib: a phenylamino-pyrim ...... CR-ABL, KIT and PDGFR kinases.

@en

Nilotinib: a phenylamino-pyrim ...... CR-ABL, KIT and PDGFR kinases.

@nl

type

label

Nilotinib: a phenylamino-pyrim ...... CR-ABL, KIT and PDGFR kinases.

@en

Nilotinib: a phenylamino-pyrim ...... CR-ABL, KIT and PDGFR kinases.

@nl

prefLabel

Nilotinib: a phenylamino-pyrim ...... CR-ABL, KIT and PDGFR kinases.

@en

Nilotinib: a phenylamino-pyrim ...... CR-ABL, KIT and PDGFR kinases.

@nl

P1433

Q37298638-CFBDBE75-1395-43C9-BAB3-2D1670B2653F

P1476

Q37298638-EB1D9064-3890-44A9-B256-107949A2F1FC

P2093

Q37298638-8286529C-08E7-4E69-9A52-A979BC743C12

P2860

Q37298638-05C03CE1-63B8-404E-9D05-F14161974202

Q37298638-0B8FEB51-AE17-4144-B004-6FE4ECDDDDF9

Q37298638-0DD9E0DB-DAD0-4D36-86A0-CCFC001F75E7

Q37298638-178BA03C-8523-4B1A-8A9E-27A409EA2B02

Q37298638-1811B136-CF83-4F84-8183-0EB37D2A9574

Q37298638-1823786A-7638-4378-AAC0-E7087924EC64

Q37298638-189B6C76-6C15-4AF6-BFC8-4D62D5230990

Q37298638-28C79D39-87DF-4344-8FDF-D8AE61FC924C

Q37298638-2A6A8268-DD4B-4130-8BBB-FC0922F0F9CA

Q37298638-2CFA1A46-A956-42D3-A77E-27891D9AA7EF

P304

Q37298638-113BBCC9-6DE0-4EA0-BDAA-B22B142C560B

P31

Q37298638-779B224F-009A-489F-B8B1-CA42A8AE44B2

P356

Q37298638-BB912CEC-A8D6-4F37-B66B-A9AE1FEBF04F

P407

Q37298638-B460A2B1-D7D5-4A16-9ECD-6A44B8D21E81

P433

Q37298638-610A92C8-A35A-42B9-8644-A9911028394C

P478

Q37298638-892EDFF5-DB9C-4363-9AE8-086047213ADA

P50

Q37298638-5424488C-E32A-46E7-90A1-C3CB07B304AC

P577

Q37298638-E76D4290-F070-4357-9ACD-6C6588BD75AC

P698

Q37298638-040F17D2-A372-4304-8E53-97934AF5BEE1

P356

14796694.4.5.611

P1433

Future Oncology

P1476

Nilotinib: a phenylamino-pyrim ...... CR-ABL, KIT and PDGFR kinases.

@en

P2093

Alfonso Quintás-Cardama

http://www.w3.org/2001/XMLSchema#string

P2860

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Crystal structure of the tyrosine kinase domain of the human insulin receptor

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Rational design of inhibitors that bind to inactive kinase conformations

P304

611-621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14796694.4.5.611

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18922118

http://www.w3.org/2001/XMLSchema#string